vs

Side-by-side financial comparison of Editas Medicine, Inc. (EDIT) and TEJON RANCH CO (TRC). Click either name above to swap in a different company.

Editas Medicine, Inc. is the larger business by last-quarter revenue ($24.7M vs $21.1M, roughly 1.2× TEJON RANCH CO). TEJON RANCH CO runs the higher net margin — 7.5% vs -22.7%, a 30.2% gap on every dollar of revenue. On growth, TEJON RANCH CO posted the faster year-over-year revenue change (17.7% vs -19.2%). Over the past eight quarters, Editas Medicine, Inc.'s revenue compounded faster (366.9% CAGR vs 68.8%).

Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.

Tejon Ranch Company, based in Lebec, California, is one of the largest private landowners in California. The company was incorporated in 1936 to organize the ownership of a large tract of land that was consolidated from four Mexican land grants acquired in the 1850s and 1860s by ranch founder Edward Fitzgerald Beale.

EDIT vs TRC — Head-to-Head

Bigger by revenue
EDIT
EDIT
1.2× larger
EDIT
$24.7M
$21.1M
TRC
Growing faster (revenue YoY)
TRC
TRC
+36.8% gap
TRC
17.7%
-19.2%
EDIT
Higher net margin
TRC
TRC
30.2% more per $
TRC
7.5%
-22.7%
EDIT
Faster 2-yr revenue CAGR
EDIT
EDIT
Annualised
EDIT
366.9%
68.8%
TRC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EDIT
EDIT
TRC
TRC
Revenue
$24.7M
$21.1M
Net Profit
$-5.6M
$1.6M
Gross Margin
30.6%
Operating Margin
-31.3%
10.9%
Net Margin
-22.7%
7.5%
Revenue YoY
-19.2%
17.7%
Net Profit YoY
87.6%
-64.7%
EPS (diluted)
$0.03
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EDIT
EDIT
TRC
TRC
Q4 25
$24.7M
$21.1M
Q3 25
$7.5M
$12.0M
Q2 25
$3.6M
$8.3M
Q1 25
$4.7M
$8.2M
Q4 24
$30.6M
$17.9M
Q3 24
$61.0K
$10.9M
Q2 24
$513.0K
$5.7M
Q1 24
$1.1M
$7.4M
Net Profit
EDIT
EDIT
TRC
TRC
Q4 25
$-5.6M
$1.6M
Q3 25
$-25.1M
$1.7M
Q2 25
$-53.2M
$-1.7M
Q1 25
$-76.1M
$-1.5M
Q4 24
$-45.4M
$4.5M
Q3 24
$-62.1M
$-1.8M
Q2 24
$-67.6M
$957.0K
Q1 24
$-62.0M
$-914.0K
Gross Margin
EDIT
EDIT
TRC
TRC
Q4 25
30.6%
Q3 25
28.4%
Q2 25
40.9%
Q1 25
15.0%
Q4 24
42.9%
Q3 24
22.9%
Q2 24
45.3%
Q1 24
0.3%
Operating Margin
EDIT
EDIT
TRC
TRC
Q4 25
-31.3%
10.9%
Q3 25
-325.4%
-16.9%
Q2 25
-1440.6%
-48.8%
Q1 25
-1635.1%
-50.7%
Q4 24
-152.2%
11.9%
Q3 24
-107649.2%
-34.9%
Q2 24
-14016.2%
-62.4%
Q1 24
-5902.3%
-53.8%
Net Margin
EDIT
EDIT
TRC
TRC
Q4 25
-22.7%
7.5%
Q3 25
-333.0%
14.0%
Q2 25
-1487.8%
-20.6%
Q1 25
-1633.5%
-17.8%
Q4 24
-148.3%
25.0%
Q3 24
-101870.5%
-16.9%
Q2 24
-13178.8%
16.8%
Q1 24
-5458.1%
-12.3%
EPS (diluted)
EDIT
EDIT
TRC
TRC
Q4 25
$0.03
$0.05
Q3 25
$-0.28
$0.06
Q2 25
$-0.63
$-0.06
Q1 25
$-0.92
$-0.05
Q4 24
$-0.55
$0.16
Q3 24
$-0.75
$-0.07
Q2 24
$-0.82
$0.04
Q1 24
$-0.76
$-0.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EDIT
EDIT
TRC
TRC
Cash + ST InvestmentsLiquidity on hand
$146.6M
$9.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$27.3M
$475.2M
Total Assets
$186.5M
$630.5M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EDIT
EDIT
TRC
TRC
Q4 25
$146.6M
$9.5M
Q3 25
$165.6M
$3.6M
Q2 25
$178.5M
$2.5M
Q1 25
$221.0M
$12.3M
Q4 24
$269.9M
$39.3M
Q3 24
$265.1M
$27.4M
Q2 24
$279.1M
$33.0M
Q1 24
$296.2M
$35.6M
Total Debt
EDIT
EDIT
TRC
TRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$57.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
EDIT
EDIT
TRC
TRC
Q4 25
$27.3M
$475.2M
Q3 25
$13.5M
$473.2M
Q2 25
$19.2M
$471.5M
Q1 25
$62.4M
$472.5M
Q4 24
$134.3M
$473.6M
Q3 24
$175.6M
$468.3M
Q2 24
$232.0M
$469.2M
Q1 24
$294.4M
$467.4M
Total Assets
EDIT
EDIT
TRC
TRC
Q4 25
$186.5M
$630.5M
Q3 25
$201.8M
$629.6M
Q2 25
$210.6M
$618.5M
Q1 25
$263.7M
$614.6M
Q4 24
$341.6M
$608.0M
Q3 24
$327.6M
$598.0M
Q2 24
$384.8M
$590.8M
Q1 24
$440.3M
$581.6M
Debt / Equity
EDIT
EDIT
TRC
TRC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.43×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EDIT
EDIT
TRC
TRC
Operating Cash FlowLast quarter
$-36.4M
$6.1M
Free Cash FlowOCF − Capex
$-36.4M
FCF MarginFCF / Revenue
-147.3%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
3.88×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EDIT
EDIT
TRC
TRC
Q4 25
$-36.4M
$6.1M
Q3 25
$-30.8M
$-2.4M
Q2 25
$-50.2M
$-381.0K
Q1 25
$-47.8M
$-1.3M
Q4 24
$-50.8M
$14.3M
Q3 24
$-52.6M
$2.1M
Q2 24
$-57.1M
$-1.8M
Q1 24
$-49.9M
$777.0K
Free Cash Flow
EDIT
EDIT
TRC
TRC
Q4 25
$-36.4M
Q3 25
$-31.3M
$-14.6M
Q2 25
$-20.0M
Q1 25
$-47.9M
$-18.9M
Q4 24
$-51.3M
$-42.9M
Q3 24
$-55.5M
$-16.8M
Q2 24
$-60.6M
$-15.8M
Q1 24
$-51.7M
$-7.3M
FCF Margin
EDIT
EDIT
TRC
TRC
Q4 25
-147.3%
Q3 25
-414.6%
-122.2%
Q2 25
-240.6%
Q1 25
-1028.6%
-230.1%
Q4 24
-167.6%
-239.3%
Q3 24
-90998.4%
-155.2%
Q2 24
-11804.3%
-277.2%
Q1 24
-4558.9%
-99.0%
Capex Intensity
EDIT
EDIT
TRC
TRC
Q4 25
0.2%
Q3 25
5.7%
102.3%
Q2 25
0.0%
236.0%
Q1 25
2.4%
213.7%
Q4 24
1.8%
319.1%
Q3 24
4788.5%
174.3%
Q2 24
681.1%
245.5%
Q1 24
164.8%
109.5%
Cash Conversion
EDIT
EDIT
TRC
TRC
Q4 25
3.88×
Q3 25
-1.43×
Q2 25
Q1 25
Q4 24
3.19×
Q3 24
Q2 24
-1.88×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons